What is the next big thing for your company's portfolio?
To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the fourth annual Hot Indications List.The 2018 edition includes:
- Analysis of the Top Movers from last year's list
- An updated Top 100 List of indications
- Orphan Hot Indications analysis
- Insights on recent acquisitions, drug approvals, and pipeline activity